Schniering, Janine
Guo, Li
Brunner, Matthias
Schibli, Roger
Ye, Shuang
Distler, Oliver
Béhé, Martin
Maurer, Britta http://orcid.org/0000-0001-9385-8097
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII3_154490, CRSII3_154490)
Hartmann Müller-Stiftung für Medizinische Forschung
Article History
Received: 6 June 2018
Accepted: 20 July 2018
First Online: 16 August 2018
Ethics approval
: All animal experiments were approved by the cantonal authorities and performed according to the Swiss animal welfare guidelines.
: Not applicable.
: JS, MBr, RS, MBe, LG, and SY have no competing interests to declare. OD had a consultancy relationship and/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espeRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sinoxa and UCB in the area of potential treatments for scleroderma and its complications. In addition, OD has a patent mir-29 licensed for the treatment of systemic sclerosis. The real or perceived potential conflicts listed above are accurately stated.BM had grant/research support from AbbVie, Protagen, Novartis, congress support from Pfizer, Roche and Actelion. In addition, BM has a patent mir-29 licensed for the treatment of systemic sclerosis. The real or perceived potential conflicts listed above are accurately stated.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.